Drug Profile


Alternative Names: L 363586; MK 678

Latest Information Update: 12 Feb 2008

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Nonindustrial source
  • Class Antihyperglycaemics; Cyclic peptides; Nootropics
  • Mechanism of Action Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Cancer; Diabetes mellitus; Diabetic retinopathy; Macular degeneration

Most Recent Events

  • 20 Jul 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 20 Jul 2006 Discontinued - Preclinical for Macular degeneration in USA (unspecified route)
  • 07 May 2003 Discontinued - Preclinical for Diabetic retinopathy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top